Muscle Invasive Bladder Cancer | Primary Research (KOL's Insight) | Market Intelligence | Epidemiology & Market Forecast-2035

Muscle invasive bladder cancer (MIBC) spreads through the detrusor muscle of the bladder. The detrusor muscle is a large muscle found deep within the bladder wall. There is a greater chance that this cancer will spread to additional body parts. For more than 40 years, systemic therapy for advanced bladder cancers that have spread to the muscle has primarily consisted of platinum-based chemotherapy. In the last ten years, developments in sequencing technologies have made it possible to quickly characterize bladder cancer's genomic profile. For advanced bladder cancers that have spread to the muscle, platinum-based chemotherapy has been the cornerstone of systemic therapy for more than 40 years. In the last ten years, developments in sequencing technologies have made it possible to quickly characterize bladder cancer's genomic profile.

Description

The detrusor muscle of the bladder is the site of muscle invasive bladder cancer (MIBC) spread. The detrusor muscle is a substantial muscle that is embedded deep within the bladder wall. This cancer has a higher chance of spreading to various body parts. A wide range of diseases, including MIBC, have a high rate of mutations and molecular genomic instability. Transcriptome profiling enables bladder cancer molecular subtyping for more precise patient classification based on prognosis and therapeutic options.

Muscle Invasive Bladder Cancer (Epidemiology)

The third most common type of cancer in American men is bladder cancer. Each year, more than 83,000 new cases in both men and women are identified. Regarding 25% of bladder cancers, MIBC is the cause. Bladder cancer rates rise as people age. The most prevalent age range where it is found is between 75 and 84. Compared to other races, Caucasians are more likely to develop bladder cancer. However, more African-Americans die from diseases than recover from them.

Muscle Invasive Bladder Cancer -Current Market Size & Forecast Trends

The market for muscle-invasive bladder cancer (MIBC) is projected to experience significant growth, with estimates indicating a current value of approximately USD 4.26 billion in 2024, expected to reach around USD 7.28 billion by 2030, reflecting a compound annual growth rate (CAGR) of 14.5% during this period. This growth is driven by the rising incidence of bladder cancer, advancements in treatment options such as immunotherapy and targeted therapies, and increasing awareness of the disease. As research continues to focus on personalized medicine and novel drug developments, the MIBC market is well-positioned for substantial growth through 2035, particularly with ongoing innovations in treatment strategies and improved patient outcomes.

The mainstay of systemic therapy for advanced bladder cancers that have spread to the muscle for more than 40 years has been platinum-based chemotherapy. In the last ten years, developments in sequencing technologies have allowed for quick genomic characterization of bladder cancer. Our understanding of the pathogenesis of bladder cancer has increased as a result, and it has also highlighted potential gaps in current treatments. Due to the high mutational burden of advanced bladder cancer, immune checkpoint inhibitors were studied. The results showed durable responses in a subset of patients. These medicines, which are currently approved for a number of indications, show how the field of advanced bladder cancer treatment is changing. Using frequently expressed molecular targets, targeted therapies such as antibody-drug conjugates and fibroblast growth factor receptor inhibitors were also developed. The molecular characterization of the illness and the development of novel therapies have stimulated studies into improving treatment modalities for muscle-invasive bladder cancer. Novel therapies for UC have finally been developed and are rapidly altering treatment paradigms, even though cisplatin-based chemotherapy is still the preferred course of action for perioperative and first-line metastatic conditions. For patients who are deemed cisplatin-ineligible and have tumors with high PD-L1 expression, this includes the approval of 2 ICIs in the first-line setting as well as 5 ICIs in the platinum-refractory setting. Recent studies have demonstrated the efficacy of erdafintib and EV in the management of platinum-refractory advanced UC patients. By introducing these novel therapies into earlier stages of the disease, improving patient selection, and discovering new therapeutic targets, the next ten years will be devoted to building on these recent successes.

Report Highlights

Muscle Invasive Bladder Cancer - Current Market Trends

Muscle Invasive Bladder Cancer - Current & Forecasted Cases across the G8 Countries

Muscle Invasive Bladder Cancer - Market Opportunities and Sales Potential for Agents

Muscle Invasive Bladder Cancer - Patient-based Market Forecast to 2035

Muscle Invasive Bladder Cancer - Untapped Business Opportunities

Muscle Invasive Bladder Cancer - Product Positioning Vis-a-vis Competitors' Products

Muscle Invasive Bladder Cancer - KOLs Insight